Latest Safety News

Clarity Pharmaceuticals has partnered with SpectronRx to manufacture and distribute its lead prostate cancer diagnostic, Cu-64 SAR-bisPSMA, at commercial scale across the US. This agreement sets the stage for a seamless launch pending FDA approval.

CSL has secured FDA approval for ANDEMBRY®, a pioneering treatment for hereditary angioedema, enabling an immediate US launch with promising clinical results. This milestone marks a significant advance in managing a rare but debilitating condition.

Volt Resources has completed a scoping study for its Alabama Graphite Refinery, revealing robust project economics and a patented purification process that could reshape US graphite supply chains.

Lotus Resources has begun cold commissioning at its Kayelekera uranium project, targeting a Q3 2025 production restart while adopting an owner-operator mining model to reduce costs and enhance control.

Bathurst Resources reports robust cash reserves and steady profitability while progressing development of its Buller and Tenas metallurgical coal projects. The company also navigates ongoing litigation that could impact its governance.

FBR Limited has secured a pivotal engineering agreement with Samsung Heavy Industries to develop a shipbuilding automation robot, marking a significant step in industrial robotics innovation.

Aurizon has landed a major 15-year contract to manage BHP’s Copper South Australia logistics, investing $100 million in new infrastructure and promising a greener, safer transport solution.

Toubani Resources has initiated a 5,000-metre diamond drilling campaign at its Kobada Gold Project in Mali, targeting deeper mineralisation to expand its 2.2 million ounce resource and extend mine life.

Nyrada’s Phase I clinical trial for its novel drug Xolatryp has cleared safety reviews through four cohorts and will now test higher doses and longer infusions in an expanded trial design.

Amplia Therapeutics has reported a rare pathological complete response in a patient from its ACCENT trial, highlighting promising potential for its drug narmafotinib in treating advanced pancreatic cancer.

Syntara Limited has unveiled encouraging interim Phase 2a data for SNT-5505, an add-on therapy targeting myelofibrosis patients with suboptimal response to ruxolitinib. The data highlight meaningful symptom relief and spleen volume reduction, positioning the drug as a potential game-changer in a challenging treatment landscape.

Clarity Pharmaceuticals’ novel PET imaging agent Cu-SAR-Bombesin demonstrated safety and effectiveness in detecting prostate cancer recurrence missed by standard scans in its Phase II SABRE trial. The agent identified lesions in about one-third of patients with negative or equivocal standard imaging.